255 related articles for article (PubMed ID: 22895060)
21. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
22. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
24. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
25. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
26. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
27. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
28. Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Asselin BL; Fisher V
Clin J Oncol Nurs; 2014 Dec; 18(6):E107-12. PubMed ID: 25427712
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
Chand S; Mahajan RV; Prasad JP; Sahoo DK; Mihooliya KN; Dhar MS; Sharma G
Biotechnol Appl Biochem; 2020 Jul; 67(4):619-647. PubMed ID: 31954377
[TBL] [Abstract][Full Text] [Related]
30. The L-asparagine operon of Rhizobium etli contains a gene encoding an atypical asparaginase.
Ortuño-Olea L; Durán-Vargas S
FEMS Microbiol Lett; 2000 Aug; 189(2):177-82. PubMed ID: 10930734
[TBL] [Abstract][Full Text] [Related]
31. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
Fernandez CA; Stewart E; Panetta JC; Wilkinson MR; Morrison AR; Finkelman FD; Sandlund JT; Pui CH; Jeha S; Relling MV; Campbell PK
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1307-13. PubMed ID: 24771103
[TBL] [Abstract][Full Text] [Related]
32. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
[TBL] [Abstract][Full Text] [Related]
34. What makes a good new therapeutic L-asparaginase?
Beckett A; Gervais D
World J Microbiol Biotechnol; 2019 Sep; 35(10):152. PubMed ID: 31552479
[TBL] [Abstract][Full Text] [Related]
35. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
36. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.
Zalewska-Szewczyk B; Gach A; Wyka K; Bodalski J; Młynarski W
Clin Exp Med; 2009 Jun; 9(2):113-6. PubMed ID: 19184328
[TBL] [Abstract][Full Text] [Related]
37. [Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them].
Alexandrova SS; Gladilina YA; Pokrovskaya MV; Sokolov NN; Zhdanov DD
Biomed Khim; 2022 Apr; 68(2):104-116. PubMed ID: 35485484
[TBL] [Abstract][Full Text] [Related]
38. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
[TBL] [Abstract][Full Text] [Related]
40. [Cross-immunogenicity of various bacterial L-asparaginases].
D'iakov IN; Pokrovskiĭ VS; Sannikova EP; Bulushova NV; Pokrovskaia MV; Aleksandrova SS
Zh Mikrobiol Epidemiol Immunobiol; 2014; (6):100-4. PubMed ID: 25816523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]